Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug

Ipsen (EPA:IPN) said today that Teijin Pharma Ltd. won approval from the Japanese Ministry of Health, Labor and Welfare for Ipsen’s Somatuline as a therapy for gastroenteropancreatic neuroendocrine tumors. The subcutaneous drug was approved in Japan in 2012 for the treatment of acromegaly and pituitary gigantism. Get the full story at our sister site, Drug Delivery Business News. The post Ipsen wins approval for gastroenteropancreatic neuroendocrine tumor drug appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat Ipsen Teijin Pharma Source Type: news

Related Links:

ConclusionsRT seems to have created a cohort of patients with brain parenchymal changes whose clinical and cognitive impact is still unknown. These patients might require a prolonged MRI and MRA follow-up to promptly detect delayed RT-related complications and minimize their clinical consequences.
Source: Journal of Neuroradiology - Category: Radiology Source Type: research
Publication date: April 2018Source: Best Practice &Research Clinical Endocrinology &Metabolism, Volume 32, Issue 2Author(s): Giampaolo Trivellin, Laura C. Hernández-Ramírez, Jeremy Swan, Constantine A. StratakisX-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to X-LAG. GPR101...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
We report here the first case of a patient with an undiagnosed MAS presenting with an acute hydrocephalus. A 21-year-old male with gigantism and craniofacial fibrous dysplasia consulted for rapidly progressive headache. An acute obstructive hydrocephalus due to a 39  × 35-mm cystic lesion in the third ventricle was discovered and operated, obtaining hydrocephalus resolution. Pathology described a colloid cyst material and a growth hormone-secreting pituitary adenoma. Genetic study revealed the mosaic GNAS R201H mutation in the pituitary tissue, confirming a MAS diagnosis. Adequate hormonal control was a...
Source: Virchows Archiv - Category: Pathology Source Type: research
Francesco Ferra ù, Adriana Albani, Alessandro Ciresi, Carla Giordano, Salvatore Cannavò
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: The majority of the surveyed physicians reported variable adherence to the international acromegaly guidelines. Clearly, higher awareness is needed among physicians for early diagnosis and timely referral for specialist management. PMID: 29971605 [PubMed - as supplied by publisher]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
ConclusionsRT seems to have created a cohort of patients with brain parenchymal changes whose clinical and cognitive impact is still unknown. These patients might require a prolonged MRI and MRA follow-up to promptly detect delayed RT-related complications and minimize their clinical consequences.
Source: Journal of Neuroradiology - Category: Radiology Source Type: research
Publication date: April 2018Source: Best Practice &Research Clinical Endocrinology &Metabolism, Volume 32, Issue 2Author(s): Giampaolo Trivellin, Laura C. Hernández-Ramírez, Jeremy Swan, Constantine A. StratakisX-linked acrogigantism (X-LAG) is a recently described form of familial or sporadic pituitary gigantism characterized by very early onset GH and IGF-1 excess, accelerated growth velocity, gigantism and/or acromegaloid features. Germline or somatic microduplications of the Xq26.3 chromosomal region, invariably involving the GPR101 gene, constitute the genetic defect leading to X-LAG. GPR101...
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
Elderly patients with acromegaly who have comorbidities may increasingly encounter perioperative complications. However, few data are available about the risks and outcome of surgical treatment in these patients. We aimed to analyze and compare the results of transnasal transsphenoidal surgery (TTS) in elderly and younger patients.
Source: World Neurosurgery - Category: Neurosurgery Authors: Tags: Original article Source Type: research
Condition:   Acromegaly Interventions:   Drug: ONO-5788;   Drug: ONO-5788 Placebo;   Drug: Octreotide;   Drug: Octreotide Placebo Sponsor:   Ono Pharmaceutical Co. Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acromegaly | Brain | Gastroenterology | Japan Health | Neurology | Pharmaceuticals